# A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Source: https://onco.cc/trials/nct06072781/  
OnCo record `nct06072781` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pegylated liposomal doxorubicin, Paclitaxel / nab-paclitaxel, Letrozole in ovarian cancer, run by Verastem, Inc., now recruiting.

## Summary

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer is a phase 3 interventional study registered as NCT06072781 by Verastem, Inc., with 270 participants planned, started 2024-03-18 and due to reach its primary completion in 2028-10-15. Interventions recorded: avutometinib, Defactinib, Pegylated liposomal doxorubicin, Paclitaxel, Letrozole. Conditions listed: Low Grade Serous Ovarian Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06072781
- Phase: 3
- Setting: A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)
- Sponsor: Verastem, Inc.
- Enrolled: 270

## Sources

- ClinicalTrials.gov NCT06072781: https://clinicaltrials.gov/study/NCT06072781

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Letrozole (and other aromatase inhibitors)](https://onco.cc/drugs/letrozole/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pegylated liposomal doxorubicin](https://onco.cc/drugs/pegylated-liposomal-doxorubicin/)
- companies: [Verastem Oncology](https://onco.cc/companies/verastem/)

---
JSON: https://onco.cc/api/v1/entities/nct06072781.json